🇺🇸 FDA
Pipeline program

JSP191

JSP-CP-008

Phase 1 small_molecule terminated

Quick answer

JSP191 for Lower-risk Myelodysplastic Syndrome is a Phase 1 program (small_molecule) at Jasper Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Jasper Therapeutics
Indication
Lower-risk Myelodysplastic Syndrome
Phase
Phase 1
Modality
small_molecule
Status
terminated

Clinical trials